Personalized medicine: Time for one-person trials

By Nicholas J. Schork. Nature, 2015

1,061 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Pharmacology, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/1234d3897eca1863738b5c530c5f3f914cd24da4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Pharmacology

In Statistics and Probability

Citations in the corpus

ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE (2019, methodology): “[33 , 51, 66] Further, one could potentially exploit AI-based simulation studies to anticipate directions that a treatment strategy might take.”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “This needs to count in many factors such as genetic, environmental, past medical history etc [193].”
Nanoparticles in the clinic (2016, background): “Perhaps surprisingly, many approved medications do not provide benefits to all who take them and this issue stems from original clinical study design that often overlooks trends in outliers which can affect a specific subset of patients.(131) Importantly, data regarding whether a patient either resp”
Machine learning and genomics: precision medicine versus patient privacy (2018, background): “Even the most prescribed drugs for the most common conditions have very limited efficacy [1]; however, this can be be explained in great part by genomic differences between patients [2].”
European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, background): “sition of biofilms vary between the ethmoid bulla and middle turbinate((157)).”
Network-based approach to prediction and population-based validation of in silico drug repurposing (2018, background): “Focusing on just single targets results in failure to anticipate off-target toxicity, unintended beneficial effects, or multiple target interactions leading to suboptimal efficacy (6-10).”
Personalized medicine: motivation, challenges, and progress. (2018, methodology): “Randomization, blinding, washout periods, multiple endpoints, and many other design elements can be used in N-of-1 trials.(27, 31, 32)”